Search

Veracyte Inc

Suletud

SektorTervishoid

56.48 -2.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

56.04

Max

57.91

Põhinäitajad

By Trading Economics

Sissetulek

-20M

29M

Müük

-1.6M

139M

P/E

Sektori keskmine

54.533

62.58

Aktsiakasum

0.52

Kasumimarginaal

20.642

Töötajad

755

EBITDA

-11M

35M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+1.94% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

30. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

1.9B

4.6B

Eelmine avamishind

58.7

Eelmine sulgemishind

56.48

Uudiste sentiment

By Acuity

50%

50%

163 / 340 Pingereas Healthcare

Veracyte Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22. juuli 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21. juuli 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20. juuli 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Võrdlus sarnastega

Hinnamuutus

Veracyte Inc Prognoos

Hinnasiht

By TipRanks

1.94% tõus

12 kuu keskmine prognoos

Keskmine 59 USD  1.94%

Kõrge 70 USD

Madal 47 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Veracyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

8

Osta

1

Hoia

1

Müü

Sentiment

By Acuity

163 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat